HEPA

HEPA US Stock
$2.22
Open: $2.06 High: $2.29 Low: $2.05 Close: $2.213
Range: 2021-06-23 - 2021-06-24
Volume: 4,826,125
Market: Open
Powered by Finage Stock APIDelayed data
HEPA
  • CEO:
  • Employees:
  • Sector:
  • Industry:
HEPA News
Latest news about the HEPA
  • Hepion Pharmaceuticals to be Added to the Russell Microcap® Index

    EDISON, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, is pleased to announce that it is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, accor

    View More →
  • Hepion Pharmaceuticals (NASDAQ:HEPA) Is In A Good Position To Deliver On Growth Plans

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

    View More →
  • Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

    EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it has completed recruitment for its Phase 2a ‘AMBITION’ clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled. “Over the past few months, the COVID-19 pandemic, compounded by the inclement weather experienced at some of our clinical trial sites in Texas, which resulted in power outages, presented difficulties in the recruitment of subjects for the second and final dosing cohort for our Phase 2a NASH trial,” said Dr. Robert Foster, Hepion’s CEO. “However, we were able to overcome these challenges and are pleased that AMBITION is now fully enrolled. After completion of 28 days dosing with either CRV431 or placebo, study subjects will be monitored for an additional 14 day period, during which time we will continue to collect data – focusing on CRV431’s safety, tolerability, pharmacokinetics and biomarker analyses for early assessments of efficacy.” “It is certainly rewarding for the Hepion clinical team to see the conclusion of enrollment for the AMBITION trial,” said Dr. Todd M. Hobbs, Hepion’s newly appointed Chief Medical Officer. “With their hard work and perseverance, we will soon be able to see a more complete picture of the safety, PK, and early efficacy of CRV431 in patients with NASH.” The Phase 2a ‘AMBITION’ study is a single-blinded, placebo controlled trial designed to assess safety, tolerability, pharmacokinetics, and biomarker analyses for early assessments of efficacy of 75 and 225 mg CRV431. Study drug or placebo are administered orally (n=18 subjects in each dosing cohort), once daily for 28 days. Hepion will also examine several biomarkers including collagens, matrix metalloproteinases, lipidomics, genomics, liver transaminases, Pro-C3, ELF score, gene-gene, gene-protein network analysis, and Fibroscan to determine early assessments of efficacy of CRV431 in the treatment of NASH. In addition, Hepion will use AI-POWR™, its proprietary Bioinformatics and AI platform that allows for precision medicine, to optimize the understanding the activity of CRV431 in NASH, which will also guide further development of CRV431 in subsequent clinical studies. About Hepion Pharmaceuticals The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect: (646) 274-3580skilmer@hepionpharma.com

    View More →
  • Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress

    EDISON, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, announced that its Senior Vice-President, Clinical Pharmacology and Analytics, Dr. Patrick Mayo, gave a virtual presentation entitled “CRV431 – From Benchtop to Bedside Clinical Development” today at the 4th Global NASH Congress. During the presentation, Dr. Mayo discussed the role of cyclophilins (peptidyl prolyl isomerases) as a molecular target for CRV431, Hepion’s lead drug candidate for the treatment of NASH. In particular, the roles of cyclophilins A, B, and D in inflammation, fibrosis, and mitochondrial function, respectively, were discussed. Dr. Mayo then provided an overview of CRV431, with a focus on population (“Pop”) pharmacokinetic (“PK”)-pharmacodynamic (“PD”) modeling, and covariate PopPK-PD modeling. This modeling was used to both illustrate how Hepion intends to use CRV431 concentrations and outcomes to perform full trial simulations for dosage strengths in future clinical trials, as well as demonstrate the importance and clinical utility of efficacy biomarkers before trial results are obtained (‘a priori’ analyses). Dr. Mayo’s analysis was used to highlight the potential of the company’s Bioinformatics and AI program, called AI-POWR™. Dr. Mayo demonstrated Hepion’s AI-machine learning to generate a Responder Analysis, pinpoint molecular function, identify cellular function, and characterize collagen-related gene function. “We all know that clinical trials, especially in NASH, are expensive, time-consuming, and often result in sub-optimal outcomes,” commented Dr. Mayo. “Our goal is to mitigate trial risk before we take on the costs and time of conducting a trial. We feel we can best do this through the use of AI-POWRTM. We intend to show that we can model concentration – effect relationships to demonstrate target engagement for optimizing treatment, and we can identify a priori who will respond best to CRV431. Our approach builds upon the “learn and confirm” treatment paradigm pioneered by clinical pharmacologist, Dr. Lewis B. Sheiner. This allows us to simulate an entire Phase 2 or 3 clinical trial of hundreds to thousands of subjects, in silico, to investigate the benefit-risk of CRV431 in NASH or any other disease. By the time we enter later-stage clinical trials, we fully expect our actual trial read-outs to confirm our modeling using our bioinformatics “learn and confirm” strategy.” A copy of Dr. Mayo’s presentation is accessible on the Company's website at www.hepionpharma.com under "Publications" in the Pipeline section. About Hepion Pharmaceuticals The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect: (646) 274-3580skilmer@hepionpharma.com

    View More →
  • DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431

    EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced positive results from an in vivo study of CRV431 in a Diet-Induced Animal Model Of Non-alcoholic fatty liver Disease (“DIAMOND”).1 It is estimated by the National Institutes of Health, that between 3% - 12% of the U.S. adult population has NASH.2 There are currently at least 90 drug candidates targeting NASH in various stages of development.3 The majority of these drug candidates are designed to target metabolic perturbations leading to the pathogenesis of NASH and thereby seek to normalize glycemic control, lipid metabolism, and insulin resistance, to name a few. Few drug candidates directly target fibrosis, either through fibrogenesis and/or fibrolysis, despite fibrosis being a major prognostic indicator of liver-related and overall mortality.4 Hepion’s clinical drug candidate, CRV431 administered once daily orally, seeks to target fibrosis, and the company’s latest in vivo animal study further lends validity to this mechanism. “Nonclinical animal efficacy models have been designed to recapitulate human disease. However, questions remain regarding the validity of these models and whether they are truly predictive of clinical efficacy outcomes,” commented Dr. Daren Ure, Hepion’s Chief Scientific Officer. “This uncertainty can be partly alleviated by performing nonclinical studies in many different types of experimental models to test the robustness of a drug’s effects. For this reason, we have conducted 9 individual animal studies of fibrosis and found consistent and statistically significant antifibrotic effects of CRV431 in every one of these studies. Antifibrotic activity has also been observed in previously reported studies conducted by an independent U.K. laboratory that studied explanted liver and lung tissues taken from human donors. Taken together, these animal and human tissue experiments give us a great deal of confidence that CRV431 has beneficial antifibrotic effects that are expected to be borne out clinically.” “The results obtained with the DIAMOND mouse experiment confirm, once again, that CRV431 is a potent antifibrotic agent,” commented Dr. Philippe Gallay, Professor of Immunology, at the Scripps Research Institute in San Diego. “This model of NASH was originally developed by Dr. Arun Sanyal, a global leader in the development and treatment of therapies for NASH. In this study, our laboratory established NASH by feeding animals with a fat- and sugar-enriched Western diet for 34 weeks, followed by 8 weeks treatment with oral dosing of CRV431 or two comparator drugs, obeticholic acid and elafibranor. Fibrosis was reduced, as determined using Picrosirius Red staining, by 47% with CRV431, 35% with obeticholic acid, and 37% with elafibranor, relative to vehicle controls. A 47% reduction in fibrosis with CRV431 is an incredible result, and this highlights that a relatively short course of CRV431 treatment can exert beneficial effects at an advanced stage of liver disease in a model having many similarities to human NASH.” A summary of CRV431’s nonclinical in vivo antifibrotic activity is shown in the following table: ModelOral Dose(animal)Dosing DurationFibrosis Reduction (Organ)StatisticalSignificanceDIAMOND50 mg/kg(mouse)8 weeks47% (liver)Significantp<0.0001Streptozotocin (“STAM”) plus High Fat Diet (“HFD”)20 mg/kg(mouse)3 weeks57% (liver)Significantp<0.01STAM plus HFD50 mg/kg(mouse)6 weeks46% (liver)Significantp=0.03STAM plus HFD50 mg/kg(mouse)11 weeks37% (liver)Significantp=0.01STAM plus HFD50 mg/kg(mouse)10 weeks44% (liver)Significantp=0.014Western Diet + CCl450 mg/kg(mouse)6 weeks82% (liver)Significantp<0.0001Thioacetamide40 mg/kg(rat)9 weeks48% (liver)Significantp=0.008CCl450mg/kg(mouse)6 weeks43% (liver)Significantp=0.005Unilateral Ureteral Obstruction50 mg/kg(mouse)2 weeks42% (kidney)Significantp=0.0006 Dr. Patrick Mayo, Hepion’s Senior Vice-President, Clinical Pharmacology and Analytics continued, “As previously reported, we have completed the 75 mg dosing cohort with CRV431 in our ongoing Phase 2a clinical study in NASH subjects, and recruitment is continuing for the 225 mg dosing cohort. While this 28-day trial is focused on the safety and pharmacokinetics of CRV431, the data show that 75 mg CRV431 dosing decreased serum transaminases (ALT, AST) from baseline, consistent with a beneficial effect on the liver. Histologic changes are not being evaluated in this study due to the short duration of treatment, but additional evidence of therapeutic effects is being sought from an extensive multi-omics program. Thousands of genes, proteins, and lipids from patients are being monitored and analyzed with Hepion’s AI-POWR™ platform to look for potential biomarkers and early signs of CRV431 efficacy that may translate to structural and functional improvements to patient livers over the longer term. Similar multi-omic studies in DIAMOND and other nonclinical models help to strengthen predictions to apply to future clinical studies.” “Overall, this is all about helping patients and developing a comprehensive risk mitigation strategy in our drug development program,” commented Dr. Robert Foster, Hepion’s Chief Executive Officer. “We know that drug development is expensive, time-consuming, and risky. Broadly speaking, companies like Hepion are faced with two major risk hurdles – drug development risk and financing risk. We recently significantly mitigated our financing risk via a successful public offering, and now we believe we are helping reduce our clinical development risk by employing numerous nonclinical efficacy models, including the recent DIAMOND model, human explanted liver tissues, and our proprietary AI.” Dr. Foster concluded, “We are relying on the expertise of our highly experienced team to effectively use all available tools to maximize the chances of CRV431’s clinical success. In that regard, we look forward to the top-line read-out of our Phase 2a NASH study in the near future.” 1 https://doi.org/10.1016/j.jhep.2016.05.005 2 Bell, J. No one knows the size of the NASH market. BioPharma Dive. https://www.biopharmadive.com/news/no-one-knows-the-size-of-the-nash-market/554240/ (2019). 3 Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020. DelveInsight Business Research LLP. 4Taylor, R.S.; Taylor, R.J.; Bayliss, S., et al. Association Between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 158(6):1611-1625. About Hepion Pharmaceuticals The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect: (646) 274-3580skilmer@hepionpharma.com

    View More →
  • Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference

    EDISON, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced its participation in the Benzinga Biotech Small Cap Conference on Thursday, March 25, 2021. Details are as follows: Dr. Robert Foster, Hepion’s Chief Executive Officer, will present a corporate overview at 9:45 a.m. Eastern TimeDr. Patrick Mayo, the Company’s Senior Vice-President, Clinical Pharmacology and Analytics, will participate in the “NASH: The Race to Find a Treatment” panel at 1:00 p.m. Eastern Time Individuals interested in attending the event can register online here. About Hepion Pharmaceuticals The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space. For further information, please contact: Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect: (646) 274-3580skilmer@hepionpharma.com

    View More →
  • Hepion Pharmaceuticals to Present on CRV431 and AI-POWR at NASH-TAG 2021

    EDISON, NJ / ACCESSWIRE / March 11, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced that it will present at the NASH-TAG 2021 Conference, being held virtually on March 11-13.

    View More →
  • Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering

    EDISON, NJ / ACCESSWIRE / February 18, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), today announced the closing of its previously announced public offering of 44,200,000 shares of its common stock at a public offering price of $2.

    View More →
  • Hepion Pharmaceuticals Announces Pricing of Public Offering

    EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the pricing of its underwritten public offering of 44,200,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $88.4 million before deducting underwriting discounts, commissions and other offering expenses. All of the shares of common stock are being offered by the Company. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. The offering is expected to close on February 18, 2021, subject to satisfaction of customary closing conditions. Hepion intends to use the net proceeds from the offering to fund research and development activities, as well as for working capital and other general corporate purposes. A shelf registration statement on Form S-3 (File No. 333-229534), including a base prospectus, was filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 6, 2019 and declared effective on February 19, 2019. The offering is being made only by means of a written prospectus and prospectus supplement. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and made available on the SEC’s website. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Hepion Pharmaceuticals The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals' current expectations and include statements regarding the offering, the expected timing of the closing of the offering and the planned use of proceeds therefrom. Actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the satisfaction of all conditions to, and the closing of, the offering. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect: (646) 274-3580skilmer@hepionpharma.com

    View More →
  • Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

    EDISON, NJ / ACCESSWIRE / February 12, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion Pharmaceuticals" or the "Company") today announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

    View More →
  • Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer

    EDISON, NJ / ACCESSWIRE / February 10, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced the appointment of Todd M.

    View More →
  • Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference

    EDISON, NJ / ACCESSWIRE / February 9, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, announced today that management will participate in the BIO CEO & Investor Digital Conference, which is being held February 16 - 18, 2021.

    View More →
  • Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director

    NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director. Dr. Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company's pre-clinical and clinical drug development programs and associated intellectual property. Dr. Thomas H. Adams (age: 78) Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. The Board believes that Dr. Adams’ executive leadership and the extensive healthcare expertise he has developed makes Dr. Adams ideally qualified to serve as an additional director of the Company. Dr. Adams, has been a director of Cardiff Oncology, Inc (NASDAQ: CRDF) ("Cardiff") since June 2018, serving in the roles of Chief Executive Officer from June 2018 to May 2020, as chairman of the board from April 2009 to December 2020 and as Executive Chairman from May through December 2020. At Cardiff, Dr. Adams led the development and repurposing of onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics, for the potential treatment of KRAS-mutated metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer and relapsed or refractory acute myeloid leukemia. He is currently a Director at Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), where he has served since 2014. Previously, Dr. Adams served as Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, from 2013 to 2019, and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. He served in several leadership roles at IRIS International, including Director, Head of Personalized Medicine and Chief Technology Officer, from 2005 until the company’s acquisition by Danaher Corporation in 2012. From 1998 to 2006, Dr. Adams was Chairman and Chief Executive Officer of Leucadia Technologies, a privately held biotechnology company which was acquired by IRIS International, Inc. in 2006. Dr. Adams founded Genta, Inc. in 1989 and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams stated, “I am excited to join the team at Tiziana to focus on developing Foralumab and Milciclib. These new targeted therapies promise to deliver relief to patients suffering from cancer, inflammatory and infectious disease. My experience in precision medicine utilizing targeted therapies with precision diagnostics should accelerate the delivery of these important therapeutics.” Gabriele Cerrone, Chairman of Tiziana, said, "We are delighted to welcome Dr. Adams to the Board and consider that his proven track record in the field of cancer could add significant value to the development of the Company's Milciclib and Foralumab oncology programs." This announcement contains inside information. Pursuant to Listing Rule 9.6.13, in connection with Dr. Adams' appointment, Dr. Adams was Executive Chairman of Synergy Pharmaceuticals Inc. until October 2018. In December 2018 Synergy Pharmaceuticals Inc. (then listed on NASDAQ), filed for Chapter 11 bankruptcy in the USA. The company currently remains in the administration process. There are no other disclosures to make pursuant to Listing Rule 9.6.13, in respect of Dr. Adams' appointment. About Tiziana Life Sciences Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients. For further enquiries:United Kingdom Investors: Tiziana Life Sciences plcGabriele Cerrone, Chairman and founder+44 (0)20 7495 2379 U.S. Investor Contact:RedChip Companies, Inc.Dave Gentry407-491-4498dave@redchip.com

    View More →
  • Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences

    EDISON, NJ / ACCESSWIRE / January 5, 2021 / Hepion Pharmaceuticals, Inc.

    View More →
  • Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

    * CRV431 Demonstrated to be Generally Safe and Well Tolerated * Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in 28 Days * Study Continuing with Higher Dose EDISON, NJ / ACCESSWIRE / December 29, 2020 / Hepion Pharmaceuticals, Inc.

    View More →
  • Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

    \\- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients -\\- DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort -\\- Final Cohort Expected to be Completed in Early 2021 -EDISON, NJ / ACCESSWIRE / December 29, 2020 / Hepion Pharmaceuticals, Inc.

    View More →
  • Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19

    \\- IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 -\\- CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - \\- Company May Seek Partnership(s) for COVID-19 Drug Development -EDISON, NJ / ACCESSWIRE / December 22, 2020 / Hepion Pharmaceuticals, Inc.

    View More →
  • Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH

    EDISON, NJ / ACCESSWIRE / December 10, 2020 / Hepion Pharmaceuticals, Inc.

    View More →
  • Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease

    \\- CRV431 May Reduce Risk of NASH-Associated Ischemic Stroke -EDISON, NJ / ACCESSWIRE / December 2, 2020 / Hepion Pharmaceuticals, Inc.

    View More →
  • Hepion Announces Closing of Public Offering of Common Stock

    Includes Full Exercise of Underwriters' Overallotment Option EDISON, NJ / ACCESSWIRE / November 30, 2020 / Hepion Pharmaceuticals, Inc.

    View More →